ISSN:
1573-7217
Keywords:
breast cancer
;
chemotherapy
;
doxorubicin
;
mitoxantrone
Source:
Springer Online Journal Archives 1860-2000
Topics:
Medicine
Notes:
Summary Weekly low dose mitoxantrone (3 mg/m2) plus doxorubicin (8 mg/m2) was administered as second-line chemotherapy to 33 patients with advanced breast cancer. Four out of 28 evaluable patients (14%) obtained a partial response with a median duration of 34 weeks (range 18–67+ weeks), while 8 patients (29%) showed stable disease with a median duration of 28 weeks (range 11+–60 weeks). Gastrointestinal toxicity and alopecia were mild. Grade II and III leukopenia occurred in 63% of the courses without serious infectious disease. Four patients experienced an asymptomatic drop of 16–20% in the left ventricular ejection fraction (LVEF) after relatively low cumulative doses of each drug, and one patient with a history of pericarditis carcinomatosa and mediastinal irradiation developed a heart failure. In conclusion, this second-line combination treatment had moderate activity in breast cancer and caused only few subjective side effects, especially with respect to gastrointestinal symptoms.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1007/BF01836959
Permalink
